ATM and gastric cancer: With respect to PARP inhibitors combined with chemotherapy, the GOLD study did not meet its primary objective of showing a significant improvement in overall survival with olaparib in combination with a chemotherapeutic agent and in the overall or ATM-negative population of Asian patients with advanced gastric cancer due to the intolerable AEs [23].